Comparison · NCT03170271-84c9d05b
Benralizumab vs Placebo: Time to First Asthma Exacerbation (up to Week 24)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Benralizumab vs Placebo: Time to First Asthma Exacerbation (up to Week 24). Trial comparisons, record NCT03170271-84c9d05b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03170271-84c9d05b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.288 | 0.247 | 0.333 | wilson | |
| Risk in group 2 | 0.467 | 0.404 | 0.532 | wilson | |
| Risk difference, group 1 minus group 2 | -0.179 | -0.256 | -0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.616 | 0.503 | 0.756 | log | |
| Odds ratio, group 1 over group 2 | 0.461 | 0.33 | 0.644 | log | |
| Number needed to treat, for one fewer participant with the outcome on Benralizumab than on Placebo | 5.58 | 3.91 | 9.85 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Benralizumab | Patients received benralizumab 30 mg administered sc in an accessorized pre-filled syringe at Week 0 (initial dose), Week 4 (loading dose), Week 8 and Week 16. An EOT visit was performed at Week 24. | 123 | 427 | OG000 |
| Group 2 | Placebo | Patients received matching placebo solution administered sc in an accessorized pre-filled syringe at Week 0 (initial dose), Week 4 (loading dose), Week 8 and Week 16. An EOT visit was performed at Week 24. | 107 | 229 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Time to First Asthma Exacerbation (up to Week 24)
- Description
Time to first asthma exacerbation was derived as follows:~Start date of first asthma exacerbation - Date of randomization + 1. The time to first asthma exacerbation for patients who did not experience an asthma exacerbation during the treatment period was censored at the EOT visit (Week 24) for patients who completed the study. Patients who withdrew from the study or were lost to follow-up before the EOT visit were censored at the last visit date after which an exacerbation could not be assessed. The median time to first asthma exacerbation was not calculated, so the number of patients who experienced an asthma exacerbation is presented for the measured values.
- Time frame
- Baseline (Week 0) up to Week 24
- Population
- The FAS included all randomized patients who received at least 1 dose of IP, irrespective of their protocol adherence and continued participation in the study.
Source ClinicalTrials.gov
Trial
- Title
- A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
- NCT number
- NCT03170271
- Phases
- PHASE3
- Conditions
- Asthma
- Interventions
- Benralizumab (Medi-563), Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03170271?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03170271-84c9d05b